LINC00324 is aberrantly expressed in 11 cancers, and dysregulated LINC00324 is also associated with poor prognosis and clinical characteristics, including tumor size, lymph node metastasis, tumor TNM stage, and clinical stage in cancer patients. Here, LINC00324 is linked to metastatic malignant neoplasm in the lymph nodes.